Appendix B

Biographical Sketches of the Workshop Planning Committee, Speakers, Panelists, and Staff

PLANNING COMMITTEE BIOSKETCHES

CARLOS BLANCO, M.D., PH.D., (Co-Chair) is the Director of the Division of Epidemiology, Services, and Prevention Research at the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH). Blanco is a national known expert in the epidemiology and treatment of addictive disorders with and without comorbid disorders. His accomplishments include, among others, a detailed examination of the course and stages of substance use disorders, the development of methods to quantify the generalizability of clinical trials, the development and testing of interventions that combine motivational interviewing with cognitive-behavioral therapy to improve retention and outcome in individuals with addictive disorders, and the creation of a virtual map of psychiatric disorders, based on empirical data, to guide research into the causes of mental disorders. Prior to joining NIDA, Blanco was professor of psychiatry at Columbia University Medical Center and a Research Psychiatrist at the New York State Psychiatric Institute. He is a graduate of Universidad Autónoma de Madrid (Spain) and completed his psychiatry residency at Columbia University, where he also completed a research fellowship. Blanco has authored more than 200 peer-reviewed publications.

CRAIG B. H. SURMAN, M.D., (Co-Chair) is Director of the Clinical and Research Program in Adult ADHD and Staff Neuropsychiatrist at Massachusetts General Hospital. Surman investigates and educates disorders of self-regulation as an associate professor of psychiatry at Harvard

Medical School. He is co-chair of the Children and Adults with ADHD (CHADD) Professional Advisory Board, and a former board member for the American Professional Society of ADHD and Related Disorders (APSARD), where he serves on the Board nominating committee. With international experts, he created “ADHD in Adults: A Practical Guide to Evaluation and Management.” An advocate for evidence-informed care, he co-authored “FAST MINDS: How to Thrive If You Have ADHD (or Think You Might).” Contributing to more than 50 investigations, he has illuminated the connection between Adult ADHD and comorbidities, and clarified the promise of novel behavioral, pharmacologic, and nutraceutical interventions for ADHD. Surman recently piloted application of remote digital measurement in ADHD treatment monitoring and in a clinical trial. To understand factors contributing to national ADHD treatment trends, he is currently collaborating with the Centers for Disease Control. He is a graduate of Oberlin College, University of Massachusetts Medical School, and completed residency and fellowship training at Harvard Medical School.

AMY F. T. ARNSTEN, PH.D., is the Albert E. Kent Professor of Neuroscience at the Yale University School of Medicine. She is an international expert on the molecular regulation of the primate prefrontal cortex, the brain region most often afflicted in ADHD, and has developed a nonstimulant treatment for ADHD, guanfacine (Intuniv), that was FDA-approved for this indication in 2009. This is one of the few examples where knowledge arising from basic science has successfully translated to a treatment for human cognitive disorders. Guanfacine is also being used off-label to treat other prefrontal cortical disorders, including cognitive deficits from long COVID. Arnsten is a member of the National Academy of Medicine and the recipient of the Goldman-Rakic Prize for Outstanding Research in Cognitive Neuroscience. She received her B.A. in neuroscience from Brown University in 1976, creating the neuroscience major, and her Ph.D. in neuroscience from University of California, San Diego, in 1982.

ANDREA M. CHRONIS-TUSCANO, PH.D., is the Joel and Kim Feller Professor of Psychology at the University of Maryland (UMD), College Park, and the Director of the UMD Students Understanding College Choices Encouraging and Executing Decisions for Success (SUCCEEDS) College Attention-Deficit/Hyperactivity Disorder (ADHD) Clinic. Chronis-Tuscano’s research focuses broadly on understanding early predictors of developmental outcomes for children with ADHD (including depression and alcohol/substance use) and developing novel treatments which target these early risk and protective factors. Much of this research has addressed issues related to maternal parenting and psychopathology (namely, maternal depression and ADHD).

Most recently, she has utilized hybrid effectiveness-implementation designs to develop treatments that can be implemented in community settings such as pediatrics and schools. Chronis-Tuscano is also the president-elect of the Society for Clinical Child and Adolescent Psychology (APA Division 53); Past-president of the International Society for Research in Child and Adolescent Psychopathology; past associate editor of the Journal of Consulting & Clinical Psychology; fellow of the Association for Psychological Science; fellow of the Association for Behavioral & Cognitive Therapies (ABCT); former associate editor of the Journal of Clinical Child & Adolescent Psychology; and former standing member of the National Institute of Mental Health (NIMH) Mental Health Services Research (SERV) review committee. She is the recipient of multiple National Institute of Health (NIH) grants and has served on several NIH review committees relevant to developmental psychopathology and interventions.

TALEED EL-SABAWI, J.D., PH.D., is an interdisciplinary scholar with degrees in public health, health services management and policy and a doctoral cognate in political science. Her area of expertise is in addiction and mental health policy, politics, and law, specifically contemporary issues at the intersection of addiction, race, and policing. El-Sabawi, a person with lived experience with ADD and adult diagnosis of ADD, has been personally affected by the stimulant shortage. In addition to her scholarship, El-Sabawi has advised federal, state, and local governments, including the Office of National Drug Control Policy, U.S. Department of Justice, Jails Division, and North Carolina’s Attorney General’s Office. She has drafted a model law for the creation of non-police behavioral health crisis response teams, which is being circulated by organizers in New Orleans (LA), Nashville (TN), Columbus (OH), Chicago (IL), Boston (MA), and Durham (NC). El-Sabawi is on the advisory circle of the North Carolina Urban Survivors Union, a chapter of the Urban Survivors Union, serves on the Board of Directors for Next Distro, and frequently works alongside persons who use drugs advocating for policy reform.

EVELYN POLK GREEN, M.S.ED., is a past national president of both the Attention Deficit Disorder Association (ADDA) and Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD). She is an adult with attention-deficit/hyperactivity disorder (ADHD), and the mother of two adult sons both of whom also have ADHD. Active in ADHD and mental health advocacy for close to 30 years, she has served as a leader representing the family voice in the ADHD and mental health communities in many capacities, including as a member of the Network on Children’s Mental Health Services funded by the MacArthur Foundation. She frequently represents the family/consumer perspective on

mental health issues and often speaks to audiences and the media on a variety of topics. She has been focused on the challenges of ADHD in minority, poor, and other underserved populations throughout her advocacy career. She is the recipient of several honors for her volunteer work in mental health and education, including the Beacon College Achieving Lifetime Vision and Excellence (ALiVE) Award for her advocacy work on behalf of children and adults with learning differences and ADHD. Green works as an administrator with the Chicago Public Schools, planning professional development programs for early childhood special education professionals and families. She holds bachelor and master’s degrees from National Louis University and a master’s degree from Northern Illinois University.

STEVE S. LEE, PH.D., is a professor of psychology and the director of clinical psychology training in the Department of Psychology at the University of California, Los Angeles (UCLA). He completed his undergraduate degree in psychology at the University of Chicago, his doctoral training in clinical psychology at the University of California, Berkeley, and then post-doctoral training in psychiatric genetics at the University of Chicago. He is an expert in the origins, development, and outcomes of youth with ADHD and related disruptive behavior and emotional problems. His program of research leverages diverse methods spanning microanalytic coding of behavior and longitudinal designs to meta-analytic reviews. Lee was past secretary/treasurer of the International Society for Research in Child and Adolescent Psychopathology and past-president of the Society for Clinical Child and Adolescent Psychology. He was the recipient of the 2021 Mavis Hetherington Award for Excellence in Applied Developmental Science from the American Psychological Association.

JAMES (JIMMY) LEONARD, PHARM.D., DABAT, is the Director of Clinical Services for the Maryland Poison Center and an associate professor at the University of Maryland School of Pharmacy. His practice and research focus on management and prevention of poisoning including exploratory ingestions in children, medication errors in all populations, and self-harm attempts in adolescents and adults. He is a member of the American Association of Clinical Toxicology and America’s Poison Centers (formerly American Association of Poison Control Centers). He is the chair of the data access committee for America’s Poison Centers. He attended Washington State University for undergraduate and pharmacy school, followed by a one-year hospital residency in Olympia, Washington. After completion of residency, he did a two-year fellowship in Clinical Toxicology from 2017 to 2019 before joining the staff at the Maryland Poison Center and subsequently the faculty at the University of Maryland School of Pharmacy.

TAMARA ROSIER, PH.D., is founder of the Attention-Deficit/Hyperactivity Disorder (ADHD) Center of West Michigan, where she and her staff of coaches and therapists work with individuals with ADHD (and their families) to learn strategies and develop new skills to live effectively with ADHD. Rosier’s experiences as a college administrator, a professor, and a high school teacher afforded her valuable insight into ADHD and how it affects one’s life. She is also the president of the ADHD Coaches Organization and co-chair of the International Conference on ADHD. She has published numerous articles about living with ADHD and frequently speaks at conferences. Her book, Your Brain’s Not Broken, provides strategies for managing the emotional aspects of ADHD.

MATTHEW RUDORFER, M.D., is a longtime Medical Officer at the National Institute of Mental Health (NIMH), and serves as Chief of the Psychopharmacology, Somatic, and Integrated Treatment Research Program, Treatment and Preventive Interventions Research Branch, in the NIMH Division of Services and Intervention Research. In this capacity he oversees grants and contracts supporting clinical trials, including pharmacotherapy studies, primarily in adults suffering from a range of mental disorders. In the past he served for a dozen years as Program Chair or Co-Chair of the annual New Clinical Drug Evaluation Unit (NCDEU) national treatment research meeting, which brought together clinical investigators from Government, academia, and industry. Following a term as Member and Chair of the FDA Psychiatric Drugs Advisory Committee, he remains an ad hoc voting member, providing uncompensated service to multiple advisory committees over the years. He is also past Editor-in-Chief of the peer-reviewed Psychopharmacology Bulletin. At present, he serves on the editorial boards of CNS Drugs and the Journal of ECT. In addition to his work at NIMH, Dr. Rudorfer maintains a small private practice in psychiatry and psychopharmacology. He is Board-Certified in Psychiatry and Clinical Pharmacology and is a member of the American Society of Clinical Pharmacology and Therapeutics (ASCPT), the American Society of Clinical Psychopharmacology (ASCP), the Society of Biological Psychiatry, and the American Psychiatric Association. At present, he is Chair of the Continuing Medical Education (CME) Committee of the Washington Psychiatric Society. After receiving his medical degree from the State University of New York, Downstate College of Medicine, Rudorfer undertook his residency in Psychiatry at Washington University in St. Louis, followed by a National Institute of General Medical Science (NIGMS) Fellowship in Clinical Pharmacology, prior to launching his research career, studying novel medications for the treatment of mood disorders, in the NIMH intramural program.

ALMUT G. WINTERSTEIN, PH.D., is distinguished professor in pharmaceutical outcomes and policy, affiliate professor in Epidemiology, and the founding director of the Center for Drug Evaluation and Safety at the University of Florida. In 2017, she was named the Dr. Robert and Barbara Crisafi Chair for Medication Safety in recognition of her research on drug safety and on devising ways to improve medication use. Winterstein’s research interests center on the post-marketing evaluation of drugs in pediatrics and pregnancy, infectious disease and psychiatry and the evaluation of policy surrounding medication use using real-world data. As expert in drug safety, she has chaired the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee from 2012–2018. Winterstein was inducted as a fellow of the International Society of Pharmacoepidemiology in 2013 and served as president of the society from 2019–2020. Since 2019 she serves as director of the Consortium for Medical Marijuana Clinical Outcomes Research, a state-funded consortium of 9 universities in Florida. In 2022 she was inducted in the Academy of Science, Engineering and Medicine in Florida. She received her pharmacy degree from Friedrich Wilhelm University in Bonn, Germany, and her Ph.D. in pharmacoepidemiology from Humboldt University in Berlin.

STEVIN H. ZORN, PH.D., is currently president and CEO of MindImmune Therapeutics. Zorn is a neuropharmacologist with extensive executive experience throughout the pharmaceutical value chain and has more than 30 years of drug discovery and drug development success across a broad range of neuro and psychiatric disorders. Prior to co-founding MindImmune Therapeutics in 2016, Zorn was Executive Vice President and Site head for Neuroscience Research for Lundbeck’s USA Research Site, Lundbeck Research U.S.A., and board member for Lundbeck USA. He has been a member of Lundbeck’s Global Research Committee, Development Committee, Research and Development (R&D) Management Group, the R&D Executive Committee and U.S. R&D Management Group. He conceived of and built one of the first Neuroinflammation Disease Biology Units in the industry. There he established a talented group of scientists that brought together disciplines of immunology, inflammation, and neuroscience to capitalize on the recently growing knowledge base showing the relationship between neuroinflammation and central nervous system diseases to advance new approaches for the treatment of mental illness. This became Lundbeck U.S.A.’s primary area of focus. Prior to Lundbeck, Zorn was with Pfizer Global Research and Development for nearly 20 years. He held positions including head of General Pharmacology, Alzheimer’s Disease Clinical Development Team Leader, Head of Psychotherapeutics Biology, Head of Neuroscience Therapeutics, Co-Chair of the Global Neuroscience Therapeutic Area Leadership Team including accountability for all R&D

as well as commercialization, and was Vice President and Global Therapeutic Area Head for Central Nervous System Disorders Research at Pfizer including chair of the Global Research Therapeutic Area Leadership Team. Zorn became Pfizer’s first global head of Neuroscience Research, was co-architect of what became the company’s overall Neuroscience area strategy and co-led the second largest and among the most productive therapeutic areas at Pfizer. As member of the Discovery Research Management Team of the Ann Arbor Pfizer site, Zorn was also jointly accountable for site deliverables from five therapeutic areas: neuroscience, cardiovascular, inflammation, dermatology, and infectious diseases. Across his industry career, Zorn shepherded or led research generating dozens of drug candidates from Lundbeck and Pfizer in clinical development for multiple indications; many have progressed to phase II/III or have advanced into commercialization. In conjunction with his responsibilities as President and CEO of MindImmune Therapeutics, Inc., Zorn is a Ryan Research Professor of Neuroscience at the University of Rhode Island. Zorn received a B.S. degree in chemistry from Lafayette College, Easton, Pennsylvania, and M.S. and Ph.D. degrees in neurotoxicology and neuropharmacology, respectively, from the University of Texas Graduate School of Biomedical Sciences, Houston, Texas. Subsequent postdoctoral research studies centered on basic research of brain and intracellular neuronal signaling mechanisms at the Rockefeller University, New York, New York, in the laboratory of Paul Greengard (Nobel Laureate).

SPEAKER AND PANELIST BIOSKETCHES

KEVIN ANTSHEL, PH.D., is a professor of psychology and associate department chair at Syracuse University. Antshel’s programmatic line of research focuses on better understanding the heterogeneity of ADHD with a specific emphasis on college student attention-deficit/hyperactivity disorder (ADHD). He is a board-certified clinical child and adolescent psychologist who maintains an active clinical practice devoted to ADHD.

AMELIA M. ARRIA, PH.D., is a professor and the director of the Center on Young Adult Health and Development in the Department of Behavioral and Community Health at the University of Maryland School of Public Health. Her research focuses on mental health and substance use problems among adolescents and young adults, including the nonmedical use of prescription drugs. Her most recent work has clarified the impact of substance use on academic achievement. She led the NIDA-funded prospective College Life Study, which investigated the behavioral health of 1,253 college students through their young adult years. She is the co-leader of the Maryland Collaborative, a network of 19 colleges working

to promote college student health with science-based strategies. She has authored more than 185 peer-reviewed publications. Her work has relevance to parents, communities, educational professionals, and policymakers. She received a B.S. from Cornell University, a PhD in epidemiology from the University of Pittsburgh and postdoctoral training in psychiatric epidemiology at Johns Hopkins University.

DAVID BAKER, MBA, has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He has been directly involved with the development and commercialization of multiple attention-deficit/hyperactivity disorder (ADHD) medications, including Adderall XR® and Vyvanse®, the two most successful ADHD brands based on annual revenue. He currently serves as an advisor to start-up life sciences companies, as a board director, and as an angel investor. Previously, he was the co-founder and CEO of Vallon Pharmaceuticals, which worked to develop abuse-deterrent stimulants for ADHD. Prior to that, he was Chief Commercial Officer and interim CEO of Alcobra Ltd., a pharmaceutical company developing a novel nonstimulant for ADHD. He worked at Shire Plc for 10 years as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing. Prior to Shire, he worked at Merck & Co. in marketing, sales, market research, and business development. Mr. Baker earned a BA in economics and computer science from Duke University, and an MBA from Duke’s Fuqua School of Business.

KYLIE BARRON, M.P.H., was diagnosed with attention-deficit/hyperactivity disorder (ADHD) as a teenager and feels most at home working within the ADHD community. She is the Vice President of the Attention Deficit Disorder Association (ADDA) and has served as the Marketing Communications Chair on the Board of Directors since 2018. As a public health marketing professional, Kylie’s work combines innovative marketing strategies with forward-thinking health promotion techniques to catalyze positive health behavior changes within hard-to-reach audiences. Kylie spends her off-time contributing to her family’s business and working as an Advanced EMT in her community.

CRAIG BERRIDGE, PH.D., is the Patricia Goldman-Rakic Professor of Psychology at the University of Wisconsin-Madison. He has longstanding expertise in the behavioral and physiological actions of central catecholamines and catecholamine-targeting drugs, particularly psychostimulants. His lab was at the forefront in the development of experimental approaches for studying the neural mechanisms that sup-

port the procognitive actions of psychostimulants used in the treatment of attention-deficit/hyperactivity disorder (ADHD). This research definitively demonstrates that psychostimulants act directly in the prefrontal cortex to promote higher cognitive processes and identifies the catecholamine receptor mechanisms that underlie these actions. More recently he has used this information to identify non-catecholamine neurotransmitters within the prefrontal cortex that regulate higher cognitive function and that could be targeted in the development of novel treatments for cognitive dysfunction associated with ADHD.

ROBERT CALIFF, M.D., MACC, NAM, is Commissioner of Food and Drugs. President Joe Biden nominated Califf to head the U.S. Food and Drug Administration and Califf was sworn in on February 17, 2022. Previously, he served as Commissioner of Food and Drugs from February 2016 to January 2017. As the top official of the FDA, Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health. Califf served as the FDA’s Deputy Commissioner for Medical Products and Tobacco from February 2015 until his first appointment as Commissioner in February 2016. Prior to rejoining the FDA, Califf was head of medical strategy and Senior Advisor at Alphabet Inc., contributing to strategy and policy for its health subsidiaries Verily Life Sciences and Google Health. He joined Alphabet in 2019, after serving as a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,300 publications in the peer-reviewed literature. Califf became a Member of the National Academy of Medicine (formerly known as the Institute of Medicine [IOM]) in 2016, one of the highest honors in the fields of health and medicine. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and the FDA Science Board’s Subcommittee on Science and Technology. He has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging. While at Duke, Califf led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public–private partnership co-founded by the

FDA and Duke. He also served as the principal investigator for Duke’s Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory Coordinating Center. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco, and a fellowship in cardiology at Duke.

BENJAMIN CHEYETTE, M.D., PH.D., spent approximately 20 years as faculty in the UCSF Department of Psychiatry, both as an Attending and as an NIH-funded Independent Investigator focused on genetically engineered mouse models of neurodevelopment. He retired as Professor Emeritus in 2018 and has since worked in the non-profit and private sectors treating insured psychiatric outpatients. Since Jan 2021 he has been the attention-deficit/hyperactivity disorder (ADHD) Program Director at Mindful Health Solutions (MHS), an interventional (TMS & esketamine) psychiatry practice with approximately 100 providers in 4 states. At MHS he has developed training for adult psychiatrists and PMHNPs who typically arrive unprepared to diagnose and treat adult ADHD—the primary diagnosis in >15% of MHS patients and a highly comorbid secondary diagnosis in patients presenting with depression or anxiety—in line with recent US epidemiological data. MHS emphasizes Measurement-Based Care; Dr. Cheyette has accordingly developed a rapid self-administered ADHD symptom-tracking scale (the HII-5) closely modeled on the widely used PHQ-9 for depression and GAD-7 for anxiety.

ANN CHILDRESS, M.D., is President of the American Professional Society of Attention-Deficit/Hyperactivity Disorder (ADHD) and Related Disorders and is in private practice in Las Vegas, Nevada, where she specializes in the treatment of attention-deficit/hyperactivity disorder (ADHD). She has adjunct faculty appointments at the Kirk Kerkorian School of Medicine at UNLV and Touro University Nevada College of Osteopathic Medicine. Childress is board certified in psychiatry, with a subspecialty in child and adolescent psychiatry. She has authored more than 100 publications on the topic of ADHD. As an investigator, she has participated in approximately 250 clinical trials.

TIFFANY R. FARCHIONE, M.D., received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child and adolescent fellowship training at the University of Pittsburgh’s Western Psychiatric Institute and Clinic (now UPMC Western Psychiatric Hospital). Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA in 2010, she was affiliated with the University of Pittsburgh Medical Center and was on the faculty of

the University of Pittsburgh. As the Director of the Division of Psychiatry in the Office of Neuroscience at FDA, Farchione is involved in the oversight of new drug review for all psychiatric drug development activities conducted under investigational new drug applications (INDs), and the review of all new drug application (NDAs) and supplements for new psychiatric drug claims.

JESSICA GOLD, M.D., M.S., will be the Chief Wellness Officer of the University of Tennessee System and an associate professor in the Department of Psychiatry at the University of Tennessee Health and Science Center as of February 1, 2024. She was previously the Director of Wellness, Engagement, and Outreach at Washington University in St. Louis School of Medicine. She works clinically as an outpatient psychiatrist and sees faculty, staff, hospital employees, and their dependents, with special emphasis on college-aged kids. She also writes and is a regular expert for the media on mental health and been featured in, among others, The New York Times, The Atlantic, NPR, PBS News Hour, The Washington Post, and SELF. Gold is a graduate of the University of Pennsylvania with a B.A. and M.S in anthropology, the Yale School of Medicine, and completed her residency training in adult psychiatry at Stanford University where she served as chief resident.

DAVID W. GOODMAN, M.D., is assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and clinical associate professor of psychiatry and behavioral sciences at the Norton School of Medicine, State University of New York–Upstate. An internationally recognized expert, he has presented more than 600 lectures to medical specialists, authored peer-reviewed scientific papers, conducted clinical research on several of the ADHD medications now on the market, serves as a consultant to the NFL, widely quoted in national media, teaches fourth-year psychiatric residents at the Johns Hopkins School of Medicine and State University of New York-Upstate, serves as the Treasurer of APSARD (American Professional Society for ADHD and Related Disorders), and a member of the APSARD Task Force for the development of the APSARD’s U.S. Clinical Practice Guidelines for the Diagnosis and Treatment of ADHD in adults.

DUANE GORDON is President of the Attention Deficit Disorder Association (ADDA). An adult with attention-deficit/hyperactivity disorder (ADHD) himself, he has 25 years’ experience as an advocate for adults with ADHD. He was a founding member and co-leader of the Montreal Adult ADHD Support Group from 1998 to 2020. He joined ADDA in 2004 and began volunteering with ADDA in 2005. He joined ADDA’s

Communication team, volunteering as a writer, and later taking on the role of newsletter editor. In 2011, he joined ADDA’s Board as Chair of Communication. The ADDA Board of Directors is a team of exceptional leaders with ADHD, and Duane is proud and grateful they chose him to lead as president in 2016. Gordon is an in-demand speaker on topics related to adult ADHD. He retired early from a career as a technology consultant to pursue his passions as an ADHD advocate and artist. He lives in Montreal, Canada.

NAPOLEON HIGGINS, M.D., is a child, adolescent and adult psychiatrist in Houston, Texas. He is the owner of Bay Pointe Behavioral Health Services and South East Houston Research Group. Higgins received his M.D. from Meharry Medical College in Nashville, Tennessee, and he completed his residency in adult psychiatry and his fellowship in child and adolescent psychiatry at University of Texas Medical Branch at Galveston. He is the Executive Director of the Black Psychiatrists of America, CEO of Global Health Psychiatry, President of the Black Psychiatrists of Greater Houston, and Past President of the Caucus of Black Psychiatrists of the American Psychiatric Association. Dr. Higgins is co-author of Bree’s Journey to Joy: A Story about Childhood Grief and Depression, How Amari Learned to Love School Again: A Story about ADHD, Mind Matters: A Resource Guide to Psychiatry for Black Communities and author of Transition 2 Practice: 21 Things Every Doctor Must Know In Contract Negotiations and the Job Search. He also specializes in nutrition and health to improve patients’ lives mentally and physically. He emphasizes that good mental and physical health are key in the practice of psychiatry and medicine. Higgins has worked with and founded many programs that help to direct inner-city young men and women to aspire to go to college and finish their educational goals. He has worked with countless community mentoring programs and has special interest in trauma, racism, and inner-city issues and how they affect minority and disadvantaged children and communities.

PATRICK KELLY is a patient advocate who was diagnosed with attention-deficit/hyperactivity disorder (ADHD) in first grade. He started simulant therapy at diagnosis, which he continues to this day. He began to take an active role in his ADHD management seven years ago while he was getting sober. These two things had a synergistic effect; a 12-step program helped with ADHD management, and ADHD management helped sobriety. He first became involved in the Attention Deficit Disorder Association (ADDA) in 2020 and has served as a facilitator for the Young People’s Peer Support group since 2022. Despite major challenges due to ADHD and addiction, Kelly is a college graduate who lived overseas for a year and maintains close friendships. He enjoys kayaking,

self-improvement, and staying up-to-date on current events and ADHD research.

ERIKA LIETZAN, J.D., M.A., is the William H. Pittman Professor of Law and Timothy J. Heinsz Professor of Law at the University of Missouri School of Law. She focuses her scholarship and teaching primarily in the areas of health law and policy, with a special focus on FDA regulation, administrative law, and intellectual property. She has published extensively on federal regulation of biopharmaceutical research, development, and approval, as well as innovation policy. Before joining academia, she practiced law for eighteen years, including eight years as a partner in the food and drug group at Covington & Burling. She has been consistently identified by her peers in private practice as a “Best Lawyer in America” in the categories of FDA law (since 2013) and Biotechnology Law (since 2007).

ANGELA MAHOME, M.D., is the is board-certified in General Psychiatry and Child and Adolescent Psychiatry. Currently, she works in Student Wellness at the University of Chicago and as a consultant for Danville School District 118 in downstate Illinois. Upon graduating from the Medical College of Georgia, she completed her residency and fellowship at the University of Chicago Hospitals. While providing outpatient care, she received numerous invitations from schools to speak to educators about attention-deficit/hyperactivity disorder (ADHD) and while working as the medical director for an inpatient Adolescent Behavioral Health Unit, she gave a presentation to the 256 Chicago Public School nurses on ADHD which was well received. Mahome has previously served on the ADHD Expert Speaker’s Bureau for two major pharmaceutical companies and is currently on the ADDA (Attention Deficit Disorder Association) medical advisory board. She is a member of the American Academy of Child and Adolescent Psychiatry.

RYAN MCNEIL, PH.D., is an associate professor of internal medicine, public health, and anthropology at Yale University. Through his community-engaged qualitative and ethnographic research, he examines social, structural, and environmental influences on drug-related harms and the implementation of substance use interventions. His recent work has examined dynamics shaping stimulant- and polysubstance use–related harms, as well as the potential uses of prescription stimulants for addressing stimulant-related harms.

BROOKE MOLINA, PH.D., is professor of psychiatry, psychology, and pediatrics at the University of Pittsburgh and a licensed clinical psychologist. Dr. Molina conducts single- and multi-site study research on the course,

causes, and treatments of ADHD and substance use/disorder amongst children and adults with increased risk and typical-healthy populations. She has concentrated on longitudinal studies of individuals with ADHD. Dr. Molina also studies stimulant misuse prevention via development of provider clinical practice strategies and longitudinal study of adolescents and young adults prescribed stimulants in primary care. Her program of research has been federally funded since 1995 including an NIH MERIT award. She has experience working successfully with community health and education providers and community member partnerships. She directs the Youth and Family Research Program at the University of Pittsburgh (yfrp.pitt.edu), sits on multiple journal editorial boards, and is on the board, served as program chair, and is President-Elect for the American Professional Society for ADHD and Related Disorders.

KOFI OBENG, diagnosed with attention-deficit/hyperactivity disorder (ADHD) in his late twenties, has been supporting people with ADHD on this journey for most of his adult life. To gain more support for his ADHD and to help others with ADHD, he joined the Attention Deficit Disorder Association (ADDA) in 2019. Shortly after joining, he volunteered to co-facilitate ADDA’s African American/Black Diaspora + ADHD Peer Support Group. Volunteering for this leadership position led him to volunteer for several critical projects at ADDA, eventually leading to his hire as ADDA’s Executive Director. In this role, he uses his leadership skills, his background in organizational transformation, and insights gained from lived experience to advance ADDA’s mission of helping adults with ADHD discover and reach their potential.

MARK OLFSON, M.D., M.P.H., the Dollard Professor of Psychiatry, Medicine and Law and professor of epidemiology at Columbia University and Research Psychiatrist at New York State Psychiatric Institute, seeks to identify gaps between clinical science and practice in behavioral health care including a focus on improving the treatment and outcome of adults and young people with serious mental illnesses and substance use disorders. He has brought attention to problems in the quality of assessment and management of children and adults with behavioral health disorders including an emphasis on neglected and underserved populations. He has characterized unmet need for mental health services, the flow of patients into mental health care, and evolving national mental health service practice patterns. Olfson, who reports no conflicts of interest, has received numerous federal and private foundation grants, and has authored more than 600 academic papers.

JENNIFER D. OLIVA, J.D., MBA, is professor of law and Val Nolan Faculty Fellow at the Indiana University Maurer School of Law, a research scholar at Georgetown Law’s O’Neill Institute for National & Global Health Law, and a senior scholar with the UCSF/UC Law Consortium on Law, Science & Health Policy. Professor Oliva’s research and teaching interests include health law and policy, privacy law, evidence, torts, and complex litigation. Her scholarship has been published by or is forthcoming in, among other publications, the Virginia Law Review, California Law Review, Duke Law Journal, Northwestern University Law Review, UCLA Law Review, and online companions to the University of Chicago Law Review and New York University Law Review. Professor Oliva has earned numerous awards for her scholarship, teaching, and service. She was selected as a 2019 Wiet Life Science Law Scholar by the Loyola University Beazley Institute for Health Law and Policy and a 2020 Health Law Scholar by the Saint Louis University Center for Health Law Studies and the American Society of Law, Medicine & Ethics. Professor Oliva was the recipient of the 2021 Health Law Community Service Award from the AALS Section on Law, Medicine, and Health Care and the Harry S. Truman Foundation honored her with the 2019 Truman Scholarship Foundation Ike Skelton Award for her commitment to public service.

SUNNY PATEL, M.D., M.P.H., is a child, adolescent, and adult psychiatrist, serving as a Senior Advisor for Children, Youth, and Families at the Substance Abuse and Mental Health Service Administration. Prior to SAMHSA, Patel was appointed a White House Fellow and served at the Department of Homeland Security. He completed specialty fellowship training in child and adolescent psychiatry at NYU and Bellevue Hospital. He trained in adult psychiatry at Cambridge Health Alliance and was a clinical fellow at Harvard Medical School. He received his M.D. from the Mayo Clinic, an M.P.H. from Harvard, and graduated with college and departmental honors from UCLA.

J. RUSSELL RAMSAY, PH.D., ABPP, is a licensed psychologist specializing in the assessment and psychosocial treatment of adult attention-deficit/hyperactivity disorder (ADHD). Before retiring from the University of Pennsylvania in June 2023 to start his independent telepsychology practice, he was professor of clinical psychology and co-founder and clinical director of PENN’s Adult ADHD Treatment & Research Program. He has served terms on the professional advisory boards of the major ADHD organizations and is on the editorial board of the Journal of Attention Disorders. He has lectured internationally and is widely published, including five books on adult ADHD (with the sixth due in 2024). His patient guidebook, The Adult ADHD Tool Kit has been published in Spanish, French,

and Korean, and a German translation is in process; it is a recommended adult ADHD self-help book by the Association for Behavioral and Cognitive Therapies. Ramsay is a CHADD Hall of Fame inductee.

LARA ROBINSON, PH.D. M.P.H., is a Lead Health Scientist with the Child Development and Disabilities Branch in the National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention (CDC). As lead of the Applied Research and Evaluation team, she oversees work on the epidemiology of, research around risk/protective factors, health promotion programs for, and policy/programmatic evaluation of attention-deficit/hyperactivity disorder (ADHD) and Tourette syndrome activities. She received her doctoral degree in Applied Developmental Psychology from the University of New Orleans and her Master of Public Health degree from Tulane University. She also completed postdoctoral integrative research training in integrative children’s mental health at the Pennsylvania State University. Robinson is a member of National Academies of Sciences, Engineering, and Medicine Forum on Child Well-Being. Clinically, she has worked as an Early Intervention evaluator and as a mental health consultant for childcare centers.

JONATHAN RUBIN, M.D., MBA, is the CMO and Senior Vice President of R&D at Supernus Pharmaceuticals, Inc. Before joining Supernus in 2020, Dr. Rubin was CMO of Atentiv from 2018 to 2020, and a consultant to Chondrial Therapeutics from 2017 to 2018. From 2013 to 2017, Rubin was CMO of Alcobra, where he supervised the completion of two Phase III studies in attention-deficit/hyperactivity disorder (ADHD). From 2007 to 2013, Dr. Rubin was Medical Director of Clinical Development and Medical Affairs for Shire Pharmaceuticals, where he supported the company’s ADHD portfolio. Prior to Shire, Rubin was in private practice as a Developmental-Behavioral and General Pediatrician for 16 years. He was a pediatric resident at Albert Einstein/Montefiore Hospital and a fellow in ambulatory pediatrics at Boston’s Children Hospital. Rubin received his M.D. from the University of Connecticut School of Medicine, his MBA from the Columbia School of Business and his B.S. in molecular biophysics and biochemistry from Yale University.

JOSEPH SCHATZ, DNP, CRNP, PMHNP-BC, CARN-AP, is a psychiatric/mental health nurse practitioner who has been living with attention-deficit/hyperactivity disorder (ADHD) since (at least) kindergarten (which is when Mrs. M. suggested to his parents that he might benefit from repeating the grade to work on his social skills). He is the Director of Penn Nursing’s PMHNP track and treats patients across the lifespan

for conditions including ADHD. In his practice, he sees the biggest barriers to effective treatment as failure to recognize/address co-occurring trauma, failure to treat ADHD in individuals with a history of substance use disorder, and failure to diagnose ADHD in adults due to clinician discomfort. Oh, and prior authorizations. Especially prior authorizations.

LATASHA SELIBY PERKINS, M.D., is a board-certified family physician practicing in Washington, D.C., and served as the new physician director to the American Academy of Family Physicians Board of Directors. She remains active in leadership as the academy’s media ambassador, promoting the voice of the family physician. She is assistant professor at the Georgetown University School of Medicine Department of Family Medicine, where she is the course director of Community-Based Learning and chair of the DC AHEC Primary Care Mentorship Program. Seliby Perkins works clinically at MedStar Primary Care at Fort Lincoln Clinic Georgetown Family Residency Program, where she provides comprehensive care to patients of all ages. She spent eight years providing care to students at Georgetown University’s Student Health Center.

MARGARET SIBLEY, PH.D., is a professor of psychiatry and behavioral sciences at the University of Washington School of Medicine and a clinical psychologist at Seattle Children’s Hospital. She has authored more than 120 scholarly publications on attention-deficit/hyperactivity disorder (ADHD) across the lifespan with a current research portfolio funded by the National Institute of Mental Health and the Institute of Education Sciences. She is an investigator on the Multimodal Treatment of ADHD (MTA) Study, secretary of the American Professional Society for ADHD and Related Disorders (APSARD), a professional advisory board member for Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD), the Diagnosis and Screening Subcommittee Chair for the APSARD Guidelines for Adult ADHD, and associate editor of the Journal of Attention Disorders.

MARTA SOKOLOWSKA, PH.D., is the Deputy Center Director for Substance Use and Behavioral Health in FDA’s Center for Drug Evaluation and Research (CDER). She serves as the center’s executive-level leader responsible for advancing FDA’s public health response to the non-medical use of substances with abuse potential. With expertise in science-based assessment and management of drug abuse risks, Sokolowska advises senior FDA officials on shaping scientific and policy interventions and executing strategies pertaining to the use of controlled substances and behavioral health programs. She joined CDER in 2018 as Associate Director for Controlled Substances in the Office of the Center Director. Prior to joining FDA, Sokolowska held senior clinical and medical leadership roles in the

pharmaceutical industry. She earned her doctoral degree in psychology from McMaster University in Canada.

MARY SOLANTO, PH.D., is professor of pediatrics and psychiatry at the Zucker School of Medicine at Hofstra-Northwell (Long Island, New York). Prior to joining Hofstra, she was director of the attention-deficit/hyperactivity disorder (ADHD) Center at the Mount Sinai School of Medicine and associate professor of psychiatry at NYU. In 2017–2018, Solanto was a Fulbright U.S. Scholar in the Netherlands where she conducted research on treatment of ADHD in college students, Dr. Solanto developed a novel cognitive-behavioral intervention for adults with ADHD, which was the focus of a NIMH-sponsored efficacy study (American Journal of Psychiatry, 2010). With her Co-PI, Dr. Anthony Rostain, Dr. Solanto most recently received NIMH funding to revise, refine, and test the CBT intervention for the needs of college students with ADHD.

BRANDI WALKER, PH.D., is the CEO of Marie Pauline Consulting, LLC, her private practice dedicated to providing educational, clinical, and psychological guidance and expertise to organizations seeking to improve their social climate and enhance their diversity and equity awareness. She is a licensed clinical psychologist, board-certified executive leadership coach, diversity and equity trainer, and organizational consultant on mental wellness and strategic planning. Walker is a Howard University and University of Maryland, alumna and a recently retired Army officer and faculty member at Womack Army Medical Center at Fort Liberty, North Carolina. Walker spent the last (7) years working with various hospitals/clinics, and schools conducting research on children with attention-deficit/hyperactivity disorder (ADHD), their family, and various sleep variables and environmental factors. She collaboratively initiated Prince George’s County (Maryland) CHADD Chapter and the Southern Regional Support Center. Additionally, she currently conducts research with the Henry Jackson Foundation.

SARA WEISENBACH, PH.D. ABPP, is the Chief of Neuropsychology at McLean Hospital, a member of the faculty at Harvard Medical School, a board-certified clinical neuropsychologist, and a clinical translational researcher. Her career has been based on improving the quality of life for individuals with cognitive and psychiatric concerns through clinical care and innovation, cutting-edge research, education and mentorship, and service to the fields of Neuropsychology and Geriatric Psychiatry. She has been continuously funded since 2008 (NIH, VA) for her work on depression and cognition during middle-age and late life. Weisenbach earned her Ph.D. in Counseling Psychology from Colorado State University in 2005. She

then went on to complete two post-doctoral fellowships; one in Clinical and Research Neuropsychology at University of Michigan and a second Special Fellowship in Geriatrics at the VA Ann Arbor Healthcare System. Weisenbach is a nationally recognized expert in cognitive and emotional health in older adults. She has developed stepped-care models for clinical evaluation of dementia and adult attention-deficit/hyperactivity disorder (ADHD). She is President for the Society for Clinical Neuropsychology of the American Psychological Association and Co-Chair of the Geriatric Mood Disorders Task Group of the National Network of Depression Centers. She regularly serves as a reviewer for peer-reviewed journals and NIH and VA study sections.

ROBIN WEISS, M.D., has followed a long and winding path throughout her medical career. Following a residency in pediatrics at the Residency Program in Social Medicine in the Bronx in 1981, she and her husband ran a pediatric ward on the island of St. Vincent, West Indies. Returning to the United States, she completed a Robert Wood Johnson Fellowship at The Johns Hopkins School of Medicine and was lured by the former dean of her medical school, Fred Robbins, to work at the Institute of Medicine. During the eventful years between 1985 and 1991, she became Director of HIV/AIDS activities at the IOM. Later, Weiss did a second residency in psychiatry at Sheppard Pratt Hospital in Baltimore, and in 1995 established a private practice and became active in state and local health policy. She has published articles on psychiatry, science, and health policy in the New York Times and other publications.

STAFF BIOSKETCHES

CAROLYN K. SHORE, PH.D., is a senior program officer with the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine (the National Academies). She is staff director of the Forum on Drug Discovery, Development, and Translation. Before joining the National Academies, Dr. Shore was an officer on Pew’s antibiotic resistance project, leading work on research and policies to spur the discovery and development of urgently needed antibacterial therapies. She previously served as a foreign affairs officer at the U.S. Department of State, where she led an initiative on open data and innovation-based solutions to global challenges. She also served as the State Department’s representative to intergovernmental organizations focusing on food safety, plant and animal health, biosecurity, and agricultural trade policy. Previously, Dr. Shore was an American Society for Microbiology congressional fellow, working on science-based policy related to antibiotic stewardship and other public health issues. She holds a doctoral degree in Microbiology

and Molecular Genetics from Harvard University. As a graduate student, she studied anti-malarial drug resistance in Senegal and worked jointly between the Medicines for Malaria Venture, Genzyme Corporation, and the Broad Institute of Harvard and MIT to discover new anti-malarial compounds. Dr. Shore was awarded a Fulbright Fellowship for work at the University of Queensland in Brisbane, Australia, and a National Institutes of Health Training Grant for postdoctoral work at the University of Iowa.

SHEENA POSEY NORRIS, M.S., PMP, is a senior program officer on the Board on Health Sciences Policy at the National Academies of Sciences, Engineering, and Medicine’s Health and Medicine Division. In this capacity, she serves as the Director of the Forum on Neuroscience and Nervous System Disorders, which brings together leaders from government, academia, industry, and non-profit organizations to discuss key challenges and emerging issues in neuroscience research, development of therapies for nervous system disorders, and related ethical and societal issues. She has led the planning of numerous workshops and activities in the areas of basic, translational, and clinical neuroscience; bioethics; training and workforce development; global mental health; and biodetection. In addition, she served as a staff officer on the Care Interventions for Individuals with Dementia and Their Caregivers and Preventing Dementia and Cognitive Impairment consensus studies. Prior to joining the National Academies, Posey Norris worked in the Graduate School of Nursing at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Working alongside advanced practice nurse researchers, she conducted research focusing on health promoting behaviors of military spouses. Posey Norris received her M.S. from Saint Joseph’s University in Philadelphia, Pennsylvania, in experimental psychology with an emphasis in neuropsychology. Her thesis-driven research during her graduate studies focused on the neurocognitive and balance effects of multiple concussions in young adults. Posey Norris graduated magna cum laude from Lynchburg College in Virginia with a Bachelor of Science degree in psychology and Spanish (high honors).

KELSEY R. BABIK, M.P.H., CIH, is an associate program officer in the Health Medicine Division at the National Academies of Sciences, Engineering, and Medicine. In addition to this workshop, she works on projects initiated by the Committee on Personal Protective Equipment for Workplace Safety and Health. This is a standing committee at the National Academies of Sciences, Engineering, and Medicine sponsored by the National Personal Protective Technology Laboratory of the National Institute for Occupational Safety and Health, to provide a forum for discussion of

scientific and technical issues relevant to the development, certification, deployment, and use of personal protective equipment, standards, and related systems to ensure workplace safety and health. Previously, at the Risk Sciences and Public Policy Institute of the Johns Hopkins Bloomberg School of Public Health, she worked on occupational health risk assessments for first responders. She is a certified industrial hygienist, has a B.S. in molecular biology from the University of Pittsburgh, an M.P.H. from the University of Maryland, and is currently pursuing a doctorate of public health (Dr.P.H.) at the University of Illinois Chicago.

NOAH ONTJES, M.A., is an associate program officer with the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine. He currently staffs the Forum on Drug Discovery, Development, and Translation, co-leading projects on engaging community practices in clinical trials and preparing the future workforce in drug R&D. He attended Wake Forest University where he graduated with a Bachelor of Science in biology and a triple minor in bioethics, chemistry, and psychology. His interest in the multiple factors that influence one’s health paired with his love of different perspectives led him to pursue a Master of Arts in bioethics at Wake Forest University. During graduate school, he successfully defended his thesis on the reasonable person standard of disclosure in genetic research as well as collaborated on a published paper concerning the ethical considerations of electroconvulsive therapy on incapacitated patients.

MELVIN JOPPY, B.S., is a senior program assistant on the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine. He previously served as a Program Assistant at the Department of Energy (DOE) in the Office of Basic Energy Sciences. Prior to DOE, he served as the Committee Manager for the Presidential Advisory Council on HIV/AIDS (PACHA) within the U.S. Department of Health and Human Services. Joppy received his B.S. in communications from Bowie State University.

This page intentionally left blank.